Please use this identifier to cite or link to this item:
http://hdl.handle.net/1942/25726
Title: | Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis: 3-year efficacy and safety results from phase 3 future 1 trial | Authors: | Mease, Philip J. Kavanaugh, Arthur Reimold, Andreas Tahir, Hasan Rech, Juergen Hall, Stephen GEUSENS, Piet Pascale, Pellet Delicha, Evie Marie Pricop, Luminata Mpofu, Shepard |
Issue Date: | 2017 | Publisher: | BMJ PUBLISHING GROUP | Source: | ANNALS OF THE RHEUMATIC DISEASES, 76, p. 952-953 (Art N° SAT0470) | Notes: | [Mease, P. J.] Swedish Med Ctr, Seattle, WA USA. [Mease, P. J.] Univ Washington, Seattle, WA 98195 USA. [Kavanaugh, A.] UC San Diego Sch Med, La Jolla, CA USA. [Reimold, A.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA. [Tahir, H.] Barts Hlth NHS Trust, London, England. [Rech, J.] Univ Erlangen Nurnberg, Erlangen, Germany. [Hall, S.] Monash Univ, Melbourne, Vic, Australia. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Geusens, P.] Maastricht Univ Hosp, Maastricht, Netherlands. [Pascale, P.; Delicha, E. M.; Mpofu, S.] Novartis Pharma AG, Basel, Switzerland. [Pricop, L.] Novartis Pharmaceut, E Hanover, NJ USA. | Keywords: | monoclonal antibodies; Psoriatic arthritis; randomized trials and safety | Document URI: | http://hdl.handle.net/1942/25726 | Link to publication/dataset: | http://ard.bmj.com/content/76/Suppl_2/952 | ISSN: | 0003-4967 | e-ISSN: | 1468-2060 | DOI: | 10.1136/annrheumdis-2017-eular.1260 | ISI #: | 000413181402756 | Category: | M | Type: | Journal Contribution |
Appears in Collections: | Research publications |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
10.1136@annrheumdis-2017-eular.1260.pdf Restricted Access | Published version | 562.59 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.